on QUANTRO Therapeutics GmbH
QUANTRO Therapeutics Reaches Milestone in Transcriptomic Drug Discovery
QUANTRO Therapeutics GmbH, based in Vienna, announced a breakthrough in transcriptomic drug discovery, achieving simultaneous 10-target multiplex-screening. The company's proprietary QUANTROseq® platform screened a 10,000-compound diversity library, yielding validated hits with a 100% hit rate for controls. This advancement marks a significant step in efficiently targeting complex diseases like cancer and inflammation.
Dr. Michael Bauer, CEO of QUANTRO, highlighted the platform's ability to profile entire compound libraries, offering new opportunities for discovering novel targeted therapies. The platform's precision aids in creating proprietary libraries focused on previously 'undruggable' targets.
QUANTRO will present its findings at the Biotech Showcase in San Francisco and participate in the WuXi Global Forum. These events offer a platform for discussing their innovative technology and exploring strategic partnerships.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all QUANTRO Therapeutics GmbH news